"Offering a New Treatment Option for Liver Cancer After First-Line Immunotherapy"

The research team at Bundang CHA Hospital has confirmed the real-world clinical efficacy of combination therapy using immune checkpoint inhibitors nivolumab and ipilimumab in patients with advanced hepatocellular carcinoma.

From the left, Hongjae Jeon and Jeongseon Kim, professors of oncology at the Cancer Center, CHA Bundang Medical Center, CHA University. Bundang CHA Medical Center

From the left, Hongjae Jeon and Jeongseon Kim, professors of oncology at the Cancer Center, CHA Bundang Medical Center, CHA University. Bundang CHA Medical Center

View original image

The team led by Professors Hongjae Jeon and Jeongseon Kim at the Cancer Center Oncology Department of CHA University Bundang CHA Hospital announced on March 11 that they had analyzed multicenter data from four Asian countries to evaluate the treatment outcomes of this combination therapy. The results were published in the international journal "Liver International," which specializes in hepatobiliary research.


Hepatocellular carcinoma is one of the leading causes of cancer-related deaths worldwide. Recently, the combination of immune checkpoint inhibitors atezolizumab and bevacizumab has been used as the first-line standard therapy. However, evidence for subsequent treatment strategies in patients unresponsive to this therapy has been limited.


The research team analyzed 116 patients with advanced hepatocellular carcinoma who received nivolumab and ipilimumab combination therapy at six medical centers across four Asian countries: Korea, Hong Kong, Taiwan, and Singapore. About half of the patients had previously been treated with the atezolizumab and bevacizumab combination, while the other half had no prior experience with immune checkpoint inhibitor therapy.


The analysis showed that the objective response rate for the entire patient group was approximately 31%. Among patients with no prior immune checkpoint inhibitor therapy, the response rate was 42%, while those who had previously received atezolizumab and bevacizumab showed a response rate of about 20%. For patients who responded to treatment, the median duration of response was approximately 24 months, indicating a relatively long-lasting effect.


The study also identified a correlation between immune-related adverse events and treatment efficacy. Patients who experienced immune-related adverse events, such as thyroid dysfunction, during the course of treatment tended to have longer progression-free survival and overall survival than those who did not experience such adverse events.



Professor Jeon stated, "Through the accumulation of multinational data from real clinical settings, we have confirmed that the combination therapy of nivolumab and ipilimumab may be a treatment option for certain patients even after first-line immune checkpoint inhibitor therapy."

Professor Kim explained, "These results demonstrate that combining immune checkpoint inhibitors with different mechanisms of action can lead to clinical benefit in real-world patient treatment."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing